| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (NCT05415215) | Hoffmann-La Roche | 2022-07-05 |
| Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (NCT05217381) | MedSIR | 2022-02-22 |
| Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC (NCT05233696) | University of Colorado, Denver | 2022-01-04 |
| Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer (NCT05749016) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-11-01 |
| Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer (NCT05021900) | Rhizen Pharmaceuticals SA | 2021-10-13 |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868) | Rhizen Pharmaceuticals SA | 2021-10-05 |
| ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (NCT04669587) | EnhancedBio USA Inc. | 2021-07-26 |
| A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer (NCT04699630) | SCRI Development Innovations, LLC | 2021-05-03 |
| NEOZOL_Follow-up Study (NCT04899713) | Hospices Civils de Lyon | 2021-05-01 |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (NCT03685331) | Abramson Cancer Center at Penn Medicine | 2020-10-15 |
| Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer (NCT04352777) | Duke University | 2020-09-14 |
| Three Fraction Radiation to Induce Immuno-Oncologic Response (NCT03978663) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2020-09-02 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941) | Royal Marsden NHS Foundation Trust | 2020-08-11 |
| COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer (NCT04929964) | Mehwish Mooghal , MBBS | 2020-01-01 |
| Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (NCT04254263) | RenJi Hospital | 2019-12-16 |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT04042051) | Cancer Trials Ireland | 2019-11-12 |
| Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer (NCT04088032) | Alison Stopeck | 2019-10-01 |
| Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy (NCT04318223) | Consorzio Oncotech | 2019-07-16 |
| Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer (NCT03329378) | Icahn School of Medicine at Mount Sinai | 2019-01-24 |
| CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial (NCT03732339) | RenJi Hospital | 2018-08-24 |
| Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer (NCT03255577) | Memorial Sloan Kettering Cancer Center | 2017-08-17 |
| A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer (NCT02595762) | Hoffmann-La Roche | 2016-10-30 |
| The p53 Breast Cancer Trial (NCT02965950) | Haukeland University Hospital | 2016-10-01 |
| A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. (NCT01785992) | Imperial College London | 2012-10-01 |
| An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer (NCT01660542) | Yonsei University | 2011-04-01 |
| Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers (NCT01367288) | Hospices Civils de Lyon | 2010-04-01 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379) | QuantumLeap Healthcare Collaborative | 2010-03-01 |
| Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer (NCT01048918) | City of Hope Medical Center | 2008-09-04 |
| Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca (NCT00756132) | University Health Network, Toronto | 2008-08-01 |
| Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer (NCT00623233) | Eli Lilly and Company | 2008-03-01 |
| Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer (NCT00455273) | Sunnybrook Health Sciences Centre | 2006-11-01 |
| Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer (NCT01837563) | Dartmouth-Hitchcock Medical Center | 2006-09-01 |
| A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy (NCT00788489) | Ontario Clinical Oncology Group (OCOG) | 2006-01-01 |
| Hydralazine and Valproate Added to Chemotherapy for Breast Cancer (NCT00395655) | National Institute of Cancerología | 2005-06-01 |
| The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer (NCT00065325) | AstraZeneca | 2003-08-01 |
| Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women (NCT00237133) | Novartis Pharmaceuticals | 2003-03-01 |